Literature DB >> 3627157

The use of bromodeoxyuridine labeling in the human lymphocyte HGPRT somatic mutation assay.

P Ostrosky-Wegman, M R Montero, C C de Nava, R R Tice, R Albertini.   

Abstract

The autoradiographic assay developed by Strauss and Albertini (1979) to quantitate human in vivo somatic mutation at the hypoxanthine guanine phosphoribosyl-transferase locus uses tritiated thymidine to identify mutant cells by their ability to pass through 'S' phase in the presence of 6-thioguanine. An alternative method, based on the incorporation of bromodeoxyuridine (BrdUrd) into the DNA of proliferative cells, followed by differential staining with the fluorescence-plus-Giemsa method, was used to identify 3 classes of lymphocyte nuclei: (a) small darkly stained nuclei, (b) large, reddish-colored nuclei with an apparent nucleolus, and (c) large, bluish-colored nuclei. By double labeling with BrdUrd and tritiated thymidine, it was determined that only the nuclei of the third class had incorporated BrdUrd. These results demonstrate that the technique used for sister-chromatid differentiation can be used to detect putative HGPRT mutants and to determine variant frequencies at the HGPRT locus.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3627157     DOI: 10.1016/0165-7992(87)90156-4

Source DB:  PubMed          Journal:  Mutat Res        ISSN: 0027-5107            Impact factor:   2.433


  3 in total

Review 1.  The application of 5-bromodeoxyuridine in the management of CNS tumors.

Authors:  A Freese; D O'Rourke; K Judy; M J O'Connor
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

2.  The HPRT short-term assay in monitoring individuals exposed to genotoxic agents.

Authors:  R Montero; M E Gonsebatt; L A Herrera; E Rojas; P Ostrosky-Wegman
Journal:  Environ Health Perspect       Date:  1993-10       Impact factor: 9.031

3.  Somatic cell gene mutations in humans: biomarkers for genotoxicity.

Authors:  R J Albertini; J A Nicklas; J P O'Neill
Journal:  Environ Health Perspect       Date:  1993-10       Impact factor: 9.031

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.